Oral Administration of Butylated Hydroxytoluene Induces Neuroprotection in a Streptozotocin-induced Rat Alzheimer's Disease Model Via Inhibition of Neuronal Ferroptosis

Overview

Journal Mol Med

Publisher Biomed Central

Specialties General Medicine
Molecular Biology

Date 2024 Nov 7

PMID 39511487

Authors

Parisa Faraji

Elham Parandavar

Hartmut Kuhn

Mehran Habibi-Rezaei

Astrid Borchert

Elham Zahedi

Shahin Ahmadian

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is the most common human neurodegenerative disorder worldwide. Owing to its chronic nature, our limited understanding of its pathophysiological mechanisms, and because of the lack of effective anti-AD drugs, AD represents a significant socio-economic challenge for all industrialized countries. Neuronal cell death is a key factor in AD pathogenesis and recent studies have suggested that neuronal ferroptosis may play a major patho-physiological role. Since ferroptosis involves free radical-mediated lipid peroxidation, we hypothesized that enteral administration of the radical scavenger butylated hydroxytoluene (BHT) might slow down or even prevent the development of AD-related symptoms in an in vivo animal AD model.

Material And Methods: To test this hypothesis, we employed the rat model of streptozotocin-induced AD and administered butylated hydroxytoluene orally at a dose of 120 mg/kg body weight. Following BHT treatment, neuronal cell death was induced by bilateral stereotactic intraventricular injection of streptozotocin at a dose of 3.0 mg/kg body weight. Three weeks after surgery, we assessed the learning capabilities and the short-term memory of three experimental groups using the conventional y-maze test: (i) streptozotocin-treated rats (BHT pre-treatment), (ii) streptozotocin-treated rats (no BHT pre-treatment), (iii) sham-operated rats (BHT pre-treatment but no streptozotocin administration). After the y-maze test, the animals were sacrificed, hippocampal tissue was prepared and several biochemical (malonyl dialdehyde formation, glutathione homeostasis, gene expression patterns) and histochemical (Congo-red staining, Nissl staining, Perls staining) readout parameters were quantified.

Results: Intraventricular streptozotocin injection induced the development of AD-related symptoms, elevated the degree of lipid peroxidation and upregulated the expression of ferroptosis-related genes. Histochemical analysis indicated neuronal cell death and neuroinflammation, which were paralleled by aberrant intraneuronal iron deposition. The streptozotocin-induced alterations were significantly reduced and sometimes even abolished by oral BHT treatment.

Conclusion: Our data indicate that oral BHT treatment attenuated the development of AD-related symptoms in an in vivo rat model, most probably via inhibiting neuronal ferroptosis. These findings suggest that BHT might constitute a promising candidate as anti-AD drug. However, more work is needed to explore the potential applicability of BHT in other models of neurodegeneration and in additional ferroptosis-related disorders.

References

Yehye W, Rahman N, Ariffin A, Hamid S, Alhadi A, Kadir F . Understanding the chemistry behind the antioxidant activities of butylated hydroxytoluene (BHT): a review. Eur J Med Chem. 2015; 101:295-312. DOI: 10.1016/j.ejmech.2015.06.026. View

Faraji P, Borchert A, Ahmadian S, Kuhn H . Butylated Hydroxytoluene (BHT) Protects SH-SY5Y Neuroblastoma Cells from Ferroptotic Cell Death: Insights from In Vitro and In Vivo Studies. Antioxidants (Basel). 2024; 13(2). PMC: 10886092. DOI: 10.3390/antiox13020242. View

Chen Z, Zhang Y . Animal models of Alzheimer's disease: Applications, evaluation, and perspectives. Zool Res. 2022; 43(6):1026-1040. PMC: 9700500. DOI: 10.24272/j.issn.2095-8137.2022.289. View

Yang W, Kim K, Gaschler M, Patel M, Shchepinov M, Stockwell B . Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016; 113(34):E4966-75. PMC: 5003261. DOI: 10.1073/pnas.1603244113. View

Chowdhury A, Rajkumar A . Systematic review of gene expression studies in people with Lewy body dementia. Acta Neuropsychiatr. 2020; 32(6):281-292. DOI: 10.1017/neu.2020.13. View

Stockwell B, Friedmann Angeli J, Bayir H, Bush A, Conrad M, Dixon S . Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017; 171(2):273-285. PMC: 5685180. DOI: 10.1016/j.cell.2017.09.021. View

Dodson M, Castro-Portuguez R, Zhang D . NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019; 23:101107. PMC: 6859567. DOI: 10.1016/j.redox.2019.101107. View

Li Y, Zeng X, Lu D, Yin M, Shan M, Gao Y . Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis. Hum Reprod. 2020; 36(4):951-964. DOI: 10.1093/humrep/deaa363. View

Plascencia-Villa G, Perry G . Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxid Redox Signal. 2020; 34(8):591-610. PMC: 8098758. DOI: 10.1089/ars.2020.8134. View

10.

Griffiths H, Dias I, Willetts R, Devitt A . Redox regulation of protein damage in plasma. Redox Biol. 2014; 2:430-5. PMC: 3949090. DOI: 10.1016/j.redox.2014.01.010. View

11.

Hinder L, Pfaff A, Emmerich R, Michels S, Schlitzer M, Culmsee C . Characterization of Novel Diphenylamine Compounds as Ferroptosis Inhibitors. J Pharmacol Exp Ther. 2021; 378(2):184-196. DOI: 10.1124/jpet.121.000534. View

12.

Couto N, Wood J, Barber J . The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic Biol Med. 2016; 95:27-42. DOI: 10.1016/j.freeradbiomed.2016.02.028. View

13.

Botterweck A, Verhagen H, Goldbohm R, Kleinjans J, van den Brandt P . Intake of butylated hydroxyanisole and butylated hydroxytoluene and stomach cancer risk: results from analyses in the Netherlands Cohort Study. Food Chem Toxicol. 2000; 38(7):599-605. DOI: 10.1016/s0278-6915(00)00042-9. View

14.

Sultana R, Butterfield D . Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis. 2010; 19(1):341-53. DOI: 10.3233/JAD-2010-1222. View

15.

Schnurr K, Kuhn H, RAPOPORT S, Schewe T . 3,5-Di-t-butyl-4-hydroxytoluene (BHT) and probucol stimulate selectively the reaction of mammalian 15-lipoxygenase with biomembranes. Biochim Biophys Acta. 1995; 1254(1):66-72. DOI: 10.1016/0005-2760(94)00168-x. View

16.

Feldman A, Wolfe D . Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 2014; 1180:31-43. DOI: 10.1007/978-1-4939-1050-2_3. View

17.

Sharif A, Mamo J, Lam V, Al-Salami H, Mooranian A, Watts G . The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases. Transl Neurodegener. 2024; 13(1):6. PMC: 10802046. DOI: 10.1186/s40035-024-00398-w. View

18.

Suchorukova E, Kirik O, Korzhevskii D . The use of immunohistochemical method for detection of brain microglia in paraffin sections. Bull Exp Biol Med. 2010; 149(6):768-70. DOI: 10.1007/s10517-010-1048-3. View

19.

Falangola M, Lee S, Nixon R, Duff K, Helpern J . Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res. 2005; 30(2):201-5. PMC: 3959869. DOI: 10.1007/s11064-004-2442-x. View

20.

. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 18(1):88-106. PMC: 6291454. DOI: 10.1016/S1474-4422(18)30403-4. View